Grace Therapeutics, Inc. Common Stock (GRCE)

Price$2.30

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-35.60%

Price vs S&P 500 (4W)-1.70%

VGM Score23.74

Market Capitalization$35.59M

All Metrics

Book Value / Share (Quarterly)$4.19

P/TBV (Annual)1.23x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.54

Price vs S&P 500 (YTD)-41.68%

Gross Margin (TTM)65.00%

Net Profit Margin (TTM)-4435.00%

EPS (TTM)$-0.36

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-0.36

EPS (Annual)$-1.35

ROI (Annual)-20.82%

Gross Margin (Annual)60.00%

Net Profit Margin (5Y Avg)-5595.44%

Cash / Share (Quarterly)$1.21

ROA (Last FY)-17.53%

EBITD / Share (TTM)$-0.72

ROE (5Y Avg)-64.77%

Operating Margin (TTM)-2130.00%

Cash Flow / Share (Annual)$-1.09

P/B Ratio0.55x

P/B Ratio (Quarterly)0.83x

Net Income / Employee (Annual)$-401,700

Net Interest Coverage (TTM)-7.01x

ROA (TTM)-3.79%

EPS Incl Extra (Annual)$-1.35

Current Ratio (Annual)11.77x

Quick Ratio (Quarterly)14.56x

3-Month Avg Trading Volume0.59M

52-Week Price Return-22.30%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.54

P/S Ratio (Annual)177.95x

Asset Turnover (Annual)0.00x

52-Week High$5.18

Operating Margin (5Y Avg)-5314.69%

EPS Excl Extra (Annual)$-1.35

26-Week Price Return-27.67%

Quick Ratio (Annual)11.53x

13-Week Price Return-38.83%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.96x

Enterprise Value$16.92M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.40x

Pretax Margin (Annual)-9840.00%

Cash / Share (Annual)$1.61

3-Month Return Std Dev121.93%

Gross Margin (5Y Avg)67.56%

Net Income / Employee (TTM)$-186,800

ROE (Last FY)-20.82%

Net Interest Coverage (Annual)-5.12x

EPS Basic Excl Extra (Annual)$-1.35

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.36

Receivables Turnover (Annual)1.60x

ROI (TTM)-4.04%

P/S Ratio (TTM)177.95x

Pretax Margin (5Y Avg)-5595.44%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.86

Price vs S&P 500 (52W)-46.66%

Year-to-Date Return-33.53%

5-Day Price Return-14.50%

EPS Normalized (Annual)$-1.35

ROA (5Y Avg)-44.34%

Net Profit Margin (Annual)-9840.00%

Month-to-Date Return-10.51%

EBITD / Share (Annual)$-1.34

Operating Margin (Annual)-8210.00%

LT Debt / Equity (Annual)0.20x

ROI (5Y Avg)-64.77%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.36

P/TBV (Quarterly)2.25x

P/B Ratio (Annual)0.47x

Inventory Turnover (TTM)1.00x

Pretax Margin (TTM)-4435.00%

Book Value / Share (Annual)$4.86

Price vs S&P 500 (13W)-47.08%

Beta0.37x

Revenue / Share (TTM)$0.00

ROE (TTM)-4.04%

52-Week Low$1.79

mGradeD

vgmGradeD

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
GRCEGrace Therapeutics, Inc. Common Stock	—	—	D	$2.30
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Grace Therapeutics is a specialty pharmaceutical company developing drug delivery technologies for rare and orphan diseases. Its lead program, GTx-104, is a novel injectable nimodipine formulation in late-stage development for aneurysmal subarachnoid hemorrhage. The company's pipeline includes additional candidates targeting ataxia-telangiectasia, postherpetic neuralgia, and other rare disease indications.